CD300LD (Gene)

Organism:

Homo sapiens

Synonyms:CD300 molecule like family member d, CD300D, CD300LD, CLM-4, CLM-5, CMRF35-A4, CMRF35A4, ENTREZ:100131439, HGNC:16848, MIM:616301, NM_001115152, NP_001108624

Omim:OMIM:616301

Id:ENSG00000204345

Hgnc:HGNC:16848

Entrez:100131439

Ensembl:ENSG00000204345

Description:CD300 molecule like family member d

Predicted to enable transmembrane signaling receptor activity and virus receptor activity. Predicted to be involved in immune system process. Predicted to act upstream of or within regulation of interleukin-6 production and regulation of tumor necrosis factor production. Predicted to be integral component of membrane. Predicted to be active in plasma membrane. [provided by Alliance of Genome Resources, Apr 2022]

Analyze

CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View CD300LD's neighborhood in the knowledge graph.

Submit

Playbook Workflow Builder: Gene-Centric Workflow

View Gene-Centric information about the gene from a pre-built PWB workflow. View the workflow with CD300LD.

CFDE Gene-Centric Appyter

The CFDE Gene Centric Appyter Resolves and Displays Gene-Centric information from CFDE APIs. Execute the Appyter using CD300LD.

Submit

GDLPA Landing Pages Links

The Gene and Drug Landing Page Aggregator (GDLPA) finds links to primary and secondary source information from CFDE and other resources. Discover landing pages for CD300LD.

Submit

Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with CD300LD.

Results found

Linked to

	Label	Description
	GSE244730 erlotinib PC-9 0 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE131649 2 V 7 HEMIN HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE244730 0 V 1 ERLOTINIB HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE240741 L-13 TIME 4 v 6 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE195559 NOTCH1 knockout endothelial cell cardiac muscle cell stem cell 8 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE202744 CDK9 inhibition Toyocamycin 1 v 3 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE113655 phenol 3 v 4 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE240741 L-13 TIME 4 v 3 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE119369 H10 inhibition 3 v 5 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE208350 H-7 Huh-7 JHH-7 0 v 7 human dn Gene Set (Entity type)	A Gene Set from LINCS

GSE244730 erlotinib PC-9 0 v 1 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE131649 2 V 7 HEMIN HUMAN DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE244730 0 V 1 ERLOTINIB HUMAN DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE240741 L-13 TIME 4 v 6 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE195559 NOTCH1 knockout endothelial cell cardiac muscle cell stem cell 8 v 1 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE202744 CDK9 inhibition Toyocamycin 1 v 3 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE113655 phenol 3 v 4 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE240741 L-13 TIME 4 v 3 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE119369 H10 inhibition 3 v 5 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE208350 H-7 Huh-7 JHH-7 0 v 7 human dn

Gene Set (Entity type)

A Gene Set from LINCS

DISPLAY PER PAGE

CFDE Workbench

Consortium

Community

Resources

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

Consortium

Community

Resources

CFDE Workbench

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.